TLIS Talis Biomedical Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: TLIS

Price (delayed)

$9.15

Market cap

$289.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$34.12

Enterprise value

$232.86M

Talis is dedicated to transforming diagnostic testing by developing and commercializing innovative products that are designed to enable accurate, low cost and rapid molecular testing for infectious diseases at the ...

Highlights
Talis Biomedical's gross profit has soared by 158% YoY
Talis Biomedical's EPS has increased by 46% YoY and by 18% QoQ
Talis Biomedical's revenue has plunged by 56% YoY and by 2.8% from the previous quarter
TLIS's equity is down by 45% year-on-year and by 15% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: https://talis.bio
Peers: OMER OMGA

Key stats

What are the main financial stats of TLIS
Market
Shares outstanding
31.69M
Market cap
$289.92M
Enterprise value
$232.86M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.5
Price to sales (P/S)
7.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
109.12
Earnings
Revenue
$2.13M
EBIT
-$62.01M
EBITDA
-$56.93M
Free cash flow
-$53.73M
Per share
EPS
-$34.12
Free cash flow per share
-$29.56
Book value per share
$18.13
Revenue per share
$1.17
TBVPS
$52.09
Balance sheet
Total assets
$94.67M
Total liabilities
$25.56M
Debt
$19.67M
Equity
$69.12M
Working capital
$68.91M
Liquidity
Debt to equity
0.28
Current ratio
8.86
Quick ratio
8.75
Net debt/EBITDA
1
Margins
EBITDA margin
-2,667.9%
Gross margin
98.1%
Net margin
-2,905.7%
Operating margin
-3,131%
Efficiency
Return on assets
-54.2%
Return on equity
-69.5%
Return on invested capital
-211.4%
Return on capital employed
-72.2%
Return on sales
-2,905.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TLIS stock price

How has the Talis Biomedical stock price performed over time
Intraday
0.55%
1 week
-0.44%
1 month
5.54%
1 year
-91.89%
YTD
22.82%
QTD
4.57%

Financial performance

How have Talis Biomedical's revenue and profit performed over time
Revenue
$2.13M
Gross profit
$2.09M
Operating income
-$66.82M
Net income
-$62.01M
Gross margin
98.1%
Net margin
-2,905.7%
Talis Biomedical's gross profit has soared by 158% YoY
Talis Biomedical's revenue has plunged by 56% YoY and by 2.8% from the previous quarter
Talis Biomedical's net income has increased by 45% YoY and by 18% from the previous quarter
The operating income rose by 42% year-on-year and by 17% since the previous quarter

Growth

What is Talis Biomedical's growth rate over time

Valuation

What is Talis Biomedical stock price valuation
P/E
N/A
P/B
0.5
P/S
7.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
109.12
Talis Biomedical's EPS has increased by 46% YoY and by 18% QoQ
The stock's P/B is 67% above its last 4 quarters average of 0.3
TLIS's equity is down by 45% year-on-year and by 15% since the previous quarter
Talis Biomedical's revenue has plunged by 56% YoY and by 2.8% from the previous quarter
The price to sales (P/S) is 53% more than the last 4 quarters average of 5.1

Efficiency

How efficient is Talis Biomedical business performance
Talis Biomedical's return on sales has decreased by 24% YoY but it has increased by 15% QoQ
The return on invested capital has declined by 17% year-on-year and by 4% since the previous quarter
The ROE has grown by 4.5% from the previous quarter
The ROA has grown by 4.4% from the previous quarter and by 2.2% YoY

Dividends

What is TLIS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TLIS.

Financial health

How did Talis Biomedical financials performed over time
Talis Biomedical's total assets has decreased by 44% YoY and by 12% QoQ
TLIS's total liabilities is down by 40% year-on-year
The debt is 72% less than the equity
TLIS's equity is down by 45% year-on-year and by 15% since the previous quarter
The debt has contracted by 41% YoY and by 2.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.